Summary
The latest industry research shows that about 90 percent of drugs that reach clinical stage fail due to incorrect selection methods. The same applies to diagnostic markers. A crucial failure source is the imperfect identification and characterisation of biological interaction analytics in the early stages of drug discovery and biomarker identification. Surflay's innovation addresses this challenge. The company developed the unique WhisperSense technology based on the physical effect of whispering gallery modes (WGM). WhisperSense makes a full kinetic analysis of biological interations possible, uniquely applying a spatial resolution of up to 6 µm in complex biological matrixes (e.g. cell culture suspensions), also in a multiplex format. Furthermore and uniquely, it is possible to perform measurements in a wide variety of reaction vessels. For the first time, WhisperSense will allow full kinetic analyses within cell cultures and organoids. All these advances eliminate certain time consuming sample preparation steps at the customer's site and enable monitoring of running processes in real-time, leading to a more precise drug and biomarker selection.
The development is protected by 3 patents and many years of expert knowledge in the production of the special spherical microparticles. Initially, Surflay will address the public sector with its WhisperSense technology, followed by the diagnostic and pharmaceutical industry.
The development is protected by 3 patents and many years of expert knowledge in the production of the special spherical microparticles. Initially, Surflay will address the public sector with its WhisperSense technology, followed by the diagnostic and pharmaceutical industry.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/837028 |
| Start date: | 01-01-2019 |
| End date: | 30-06-2019 |
| Total budget - Public funding: | 71 429,00 Euro - 50 000,00 Euro |
Cordis data
Original description
The latest industry research shows that about 90 percent of drugs that reach clinical stage fail due to incorrect selection methods. The same applies to diagnostic markers. A crucial failure source is the imperfect identification and characterisation of biological interaction analytics in the early stages of drug discovery and biomarker identification. Surflay's innovation addresses this challenge. The company developed the unique WhisperSense technology based on the physical effect of whispering gallery modes (WGM). WhisperSense makes a full kinetic analysis of biological interations possible, uniquely applying a spatial resolution of up to 6 µm in complex biological matrixes (e.g. cell culture suspensions), also in a multiplex format. Furthermore and uniquely, it is possible to perform measurements in a wide variety of reaction vessels. For the first time, WhisperSense will allow full kinetic analyses within cell cultures and organoids. All these advances eliminate certain time consuming sample preparation steps at the customer's site and enable monitoring of running processes in real-time, leading to a more precise drug and biomarker selection.The development is protected by 3 patents and many years of expert knowledge in the production of the special spherical microparticles. Initially, Surflay will address the public sector with its WhisperSense technology, followed by the diagnostic and pharmaceutical industry.
Status
CLOSEDCall topic
EIC-SMEInst-2018-2020Update Date
27-10-2022
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
